<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784966</url>
  </required_header>
  <id_info>
    <org_study_id>VCU IRB 4196</org_study_id>
    <nct_id>NCT00784966</nct_id>
  </id_info>
  <brief_title>Islet After Kidney Transplant for Type 1 Diabetes</brief_title>
  <official_title>Pancreatic Islet Transplantation in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if prolonged administration of the anti TNF (tumor
      necrosis factor)-Alpha agent etanercept is associated with enhanced graft survival in
      patients undergoing islet after kidney transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    University decision.
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The functional capability of the islet allograft to normalize glucose metabolism in the absence of insulin therapy.</measure>
    <time_frame>Outcome measures will be assessed at protocol prescribed intervals. Long term outcomes assessment will be measured at 5 years post transplant or all evidence of islet function has ceased plus six months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in insulin requirements in those patients who do not achieve insulin independence with improved metabolic control.</measure>
    <time_frame>Outcome measures will be assessed at protocol prescribed intervals.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two weeks etanercept post islet transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two months etanercept treatment post islet transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 1 diabetes mellitus, who have a stable functioning renal
             transplant, are taking the appropriate maintenance immunosuppression and have no
             severe health problems that preclude them receiving an islet transplant will be
             considered for inclusion.

        Exclusion Criteria:

          -  Have a history of or findings suggestive of unstable diabetic complications (e.g.
             active eye disease)

          -  Active infections (clinically or by laboratory testing)

          -  History of current malignancy or suspicion of malignancy until properly investigated
             and excluded

          -  Liver or biliary abnormalities

          -  Unstable cardiovascular disease

          -  Findings to suggest immunological sensitization or those women who have the potential
             to get pregnant and are not using a sufficient method of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian H Cotterell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John N Clore, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University Health System</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2008</study_first_submitted>
  <study_first_submitted_qc>November 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <last_update_submitted>September 12, 2014</last_update_submitted>
  <last_update_submitted_qc>September 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Islet transplantation</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Kidney Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

